Rheumatology

Post hoc analyses of the phase 2 NOBILITY trial reveal that adding obinutuzumab to standard lupus nephritis therapy enhances kidney preservation and reduces glucocorticoid reliance.

Robert Wermers, MD, and Monica Richey, MSN, ANP-bc, provide management updates and guidelines for clinicians who are treating patients with osteoporosis and osteopenia in their session at the Practical...

Osteoarthritis is a common chronic and degenerative disease among adults. A group of experts estimated the disease’s burden spanning two decades and the projection of burden to 2050.

In late September, the FDA approved the first biosimilar to tocilizumab to treat adult and pediatric patients with various indications of arthritis.

Despite being approved for use, consensus among the real-world data on the use of IL-23 inhibitors in psoriatic disease has been lacking; therefore, researchers recently examined the drug survival and...

Researchers aimed to develop a risk prediction model for psoriatic arthritis progression in patients with psoriasis.

In a recent study, researchers examined the prevalence of comorbidities and risk factors in individuals with newly diagnosed psoriatic arthritis.

In a post hoc analysis of two phase 3 trials, researchers set out to determine the impact of sex on tofacitinib in terms of efficacy, safety, and time to discontinuation.

Researchers evaluated the effect of therapeutic exercise to help reduce pain in patients with knee or hip osteoarthritis.

In a post hoc analysis of the EXCEED study, researchers found that secukinumab and adalimumab—two biologic disease-modifying antirheumatic medications—showed similar efficacy in the resolution of enthesitis...